ZMC-USA, LLC has been an evolution of ideals which has merged two cultures together to maximize the strengths of both. - September 02, 2008 - ZMC-USA

Zhejiang Medicine Company, Ltd. (ZMC) located at 59 East Huanchang Road Xinchang, Zhejiang Province 312500 Peoples Republic of China proudly announces its USP grade ingredients D-alpha tocopheryl succinate, DL-alpha tocopheryl acetate and D-alpha tocopheryl acetate have been found to be in compliance with the requirements of the USP (United States Pharmacopeia) Ingredient Verification Program. - August 01, 2008 - ZMC-USA

Raw ingredient manufacturer Zhejiang Medicine Company Limited / Xinchang Pharmaceutical Factory (ZMC) has been issued patent #7,271,298 from the USPTO for the process for isolation and purification of Xanthophyll crystals from plant oleoresin. - May 17, 2008 - ZMC-USA

Zhejiang Medicine Company, Ltd. (ZMC) located at 59 East Huanchang Road Xinchang, Zhejiang Province 312500 Peoples Republic of China proudly announces its CoQ10 and Beta-Carotene USP grade ingredients have been granted the USP (United States Pharmacopeia) verification mark under USP’s voluntary Verified Dietary Supplement Ingredients Program. - March 10, 2008 - ZMC-USA

Recently released retail sales data for year ending 2007 (IRI) indicate a 19% increase in dollar sales volume and a 9% increase in unit sales of Coenzyme Q10. - January 23, 2008 - ZMC-USA

Samaritan has appointed two new independent members, Jack L. Ayala and Robert W. Crane, to its Board of Directors. Mr. Ayala and Mr. Crane bring valuable experience and their appointment strengthens Samaritan's commitment to maintain a majority of independent members that reflects today's best practices on its Board. Samaritan's board is now comprised of eight independent directors and two internal directors. - January 09, 2008 - Samaritan Pharmaceuticals

Samaritan has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 09, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals has received a notice that a European Patent has been granted to Samaritan's SP-1000 (Cholesterol Recognition Sequence) drug for the treatment of cardiovascular disease. - January 09, 2008 - Samaritan Pharmaceuticals

Enters Service Agreement with Advinus Therapeutics, India to Validate Potential Memory Restoring Benefits of Alzheimer's Drug Caprospinol. Strategy is to Bolster Caprospinol Alzheimer's Data Package to Out-License to Big Pharma and Expand IND Application to Enter Human Trials. Samaritan Pharmaceuticals... - January 09, 2008 - Samaritan Pharmaceuticals

The U.S. Food and Drug Administration (FDA) has completed its regulatory review of Samaritan's IND (Investigational New Drug) application for Cushing's syndrome SP-6300 and declared it has not identified any deficiencies in its IND filing. Accordingly, Samaritan can proceed with its proposed Phase II clinical study of Cushing's syndrome SP-6300's efficacy in patients experiencing Hypercortisolism. - January 04, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals, Inc. is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification, from the Cyprus Ministry of Health, that its marketing authorization for HIV fungus drug Amphocil has been approved in Cyprus. The Cyprus Ministry of Health is... - January 03, 2008 - Samaritan Pharmaceuticals

Ms. Anna Strasberg has joined Samaritan's Advisory Board. Anna Strasberg is best known for continuing the Actors Studio, where the work of her husband Lee Strasberg nurtured the talents of celebrities like Marlon Brando, Robert De Niro, Harvey Keitel, Paul Newman and Al Pacino. - January 03, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals has signed an exclusive licensing and distribution agreement with Three Rivers Pharmaceuticals, LLC for fungal infection drug Amphocil to add the territory of Ireland. Currently, Samaritan has the marketing rights for Amphocil in Greece and Cyprus and has successfully registered and obtained a price increase for Amphocil in Greece. - January 03, 2008 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals, Inc. has signed an exclusive distribution agreement with EUSA Pharma to launch, promote, sell and support pain patch Rapydan in Greece and Cyprus. - January 03, 2008 - Samaritan Pharmaceuticals

In an in vivo 'Proof of Concept' study, Samaritan Pharmaceuticals, Inc. has confirmed Caprospinol's (SP-233) efficacy in its ability to dramatically decrease beta amyloid plaque in the brain, accompanied by a complete recovery of memory back to baseline (p=0.002), as shown in a Morris water maze task. This study confirms previously reported in vitro data and suggests Caprospinol may not only slow the progress of Alzheimer's, but may also reverse plaque-related brain injuries associated with AD. - November 27, 2007 - Samaritan Pharmaceuticals

Samaritan announced today the appointment of James E.K. Hildreth, M.D., a world renowned physician and HIV researcher, to its Scientific Advisory Board. The work of Dr. Hildreth in HIV/AIDS dates back to 1986 and focuses on blocking HIV infection by learning how HIV gets into cells. He has published more than 80 scientific articles and holds six patents. - October 03, 2007 - Samaritan Pharmaceuticals

Reinforcing the quality presented by ZMC’s fermentation technology CoQ10, ZMC commissioned several toxicology studies performed by The Institute of Environmental Toxicology located in Ibaraki, Japan. The tests confirmed that ZMC’s coenzyme Q10 is safe at high doses. - September 07, 2007 - ZMC-USA

Samaritan announced that it has entered into an exclusive licensing agreement with Georgetown University for a patent covering the Peripheral Benzodiazepine Receptor (PBR) which has led to Cancer drug candidates with the ability to inhibit cancerous tumors; and an imaging technique that could possibly distinguish cancerous tumors for a more targeted and improved chemotherapy. - August 21, 2007 - Samaritan Pharmaceuticals

Samaritan Pharmaceuticals has exclusively licensed a patent application entitled "Structure Based Drug Design of Steroid Inhibitors" from Georgetown University. - August 16, 2007 - Samaritan Pharmaceuticals

ZMC will continue to demonstrate their commitment to safety, security, quality and reliability. ZMC is, and has always been, dedicated to providing its customers with the finest products on the market. Please be assured ZMC is as concerned about the safety and quality of food ingredients as you. - May 30, 2007 - ZMC-USA

A benchmark study was conducted by two independent labs; Faculty of Pharmaceutical Sciences at Hokkaido University and Japan Food Research Laboratories, confirming that no unknown impurities exist in ZMC CoQ10. - April 24, 2007 - ZMC-USA